Cited by 752Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismLipid metabolism and disorders

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

Open access

Cannon, Christopher P., Shah, Sukrut, Dansky, Hayes M., Davidson, Michael, Brinton, Eliot A., Gotto, Antonio M., Stepanavage, Michael, Liu, Sherry Xueyu, Gibbons, Patrice, Ashraf, Tanya B., Zafarino, Jennifer, Mitchel, Yale, Barter, Philip·2010·New England Journal of Medicine

DOI 10.1056/nejmoa1009744

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety profile of anacetrapib in patients with coronary heart disease or at high risk for coronary heart disease. Eligible patients who were taking a statin and who had an LDL cholesterol level that was consistent with that recommended in guidelines were assigned to receive 100 mg of anacetrapib or placebo daily for 18 months. The primary end points were the percent change from baseline in LDL cholesterol at 24 weeks (HDL cholesterol level was a secondary end point) and the safety and side-effect profile of anacetrapib through 76 weeks. Cardiovascular events and deaths were prospectively adjudicated. RESULTS: A total of 1623 patients underwent randomization. By 24 weeks, the LDL cholesterol level had been reduced from 81 mg per deciliter (2.1 mmol per liter) to 45 mg per deciliter (1.2 mmol per liter) in the anacetrapib group, as compared with a reduction from 82 mg per deciliter (2.1 mmol per liter) to 77 mg per deciliter (2.0 mmol per liter) in the placebo group (P<0.001)--a 39.8% reduction with anacetrapib beyond that seen with placebo. In addition, the HDL cholesterol level increased from 41 mg per deciliter (1.0 mmol per liter) to 101 mg per deciliter (2.6 mmol per liter) in the anacetrapib group, as compared with an increase from 40 mg per deciliter (1.0 mmol per liter) to 46 mg per deciliter (1.2 mmol per liter) in the placebo group (P<0.001)--a 138.1% increase with anacetrapib beyond that seen with placebo. Through 76 weeks, no changes were noted in blood pressure or electrolyte or aldosterone levels with anacetrapib as compared with placebo. Prespecified adjudicated cardiovascular events occurred in 16 patients treated with anacetrapib (2.0%) and 21 patients receiving placebo (2.6%) (P = 0.40). The prespecified Bayesian analysis indicated that this event distribution provided a predictive probability (confidence) of 94% that anacetrapib would not be associated with a 25% increase in cardiovascular events, as seen with torcetrapib. CONCLUSIONS: Treatment with anacetrapib had robust effects on LDL and HDL cholesterol, had an acceptable side-effect profile, and, within the limits of the power of this study, did not result in the adverse cardiovascular effects observed with torcetrapib. (Funded by Merck Research Laboratories; ClinicalTrials.gov number, NCT00685776.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1009744

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citation
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citation
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 498
Torcetrapib‐induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
Forrest, M. J., Bloomfield, D. M., Briscoe, R. J., Brown, P. N., Cumiskey, A., Ehrhart, J., Hershey, J. C., Keller, W. J., Ma, X., McPherson, H. E., et al. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.229 · Cited by 293
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies
Krishna, R., Anderson, M. S., Bergman, A. J., Jin, B., Fallon, M. S., Côté, J., Rosko, K., Chavez-Eng, C. M., Lutz, R., Bloomfield, D. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61813-3 · Cited by 275

Flagged first, then by citations

Show all 17 references

Sorted by citations

Items 101–200 of 752

Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease
Gotto, A. M., Cannon, C. P., Li, X. S., Vaidya, S., Kher, U., Brinton, E. A., Davidson, M., Moon, J. E., Shah, S., Dansky, H. M., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.041 · Cited by 86
Self-citation
Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease
Nomura, A., Won, H., Khera, A. V., Takeuchi, F., Ito, K., McCarthy, S., Emdin, C. A., Klarin, D. M., Natarajan, P., Zekavat, S. M., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.311145 · Cited by 86
Torcetrapib impairs endothelial function in hypertension
Simic, B., Hermann, M., Shaw, S., Bigler, L., Stalder, U., Doerries, C., Besler, C., Lüscher, T. F., & Ruschitzka, F. T. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr348 · Cited by 86
Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis
Akioyamen, L. E., Genest, J. J., Chu, A., Inibhunu, H., Ko, D. T., & Tu, J. V. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.10.012 · Cited by 86
Effect of HDL-Raising Drugs on Cardiovascular Outcomes: A Systematic Review and Meta-Regression
Kaur, N., Pandey, A. K., Negi, H., Shafiq, N., Reddy, S., Kaur, H., Chadha, N., & Malhotra, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094585 · Cited by 83
Treatment Options for Statin-Associated Muscle Symptoms
Laufs, U., Scharnagl, H., Halle, M., Windler, E., Endres, M., & März, W. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0748 · Cited by 85
Recent Advances in Preventive Cardiology and Lifestyle Medicine
Franklin, B. A., & Cushman, M. (2011) · Circulation · doi:10.1161/circulationaha.110.981613 · Cited by 82
Repeat Revascularization After Contemporary Percutaneous Coronary Intervention
Stolker, J. M., Cohen, D. J., Kennedy, K. F., Pencina, M. J., Lindsey, J. B., Mauri, L., Cutlip, D. E., & Kleiman, N. S. (2012) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.967802 · Cited by 81
HDL, Atherosclerosis, and Emerging Therapies
Hafiane, A., & Genest, J. J. (2013) · Cholesterol · doi:10.1155/2013/891403 · Cited by 82
Genome-Wide Association Study Highlights APOH as a Novel Locus for Lipoprotein(a) Levels—Brief Report
Hoekstra, M., Chen, H. Y., Rong, J., Dufresne, L., Yao, J., Guo, X., Tsai, M. Y., Tsimikas, S., Post, W. S., Vasan, R. S., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314965 · Cited by 80
CETP Inhibition: Past Failures and Future Hopes
Kosmas, C. E., DeJesus, E., Rosario, D., & Vittorio, T. J. (2016) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s32667 · Cited by 80
Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters
Castro‐Perez, J. M., Briand, F., Gagen, K., Wang, S., Chen, Y., McLaren, D. G., Shah, V., Vreeken, R. J., Hankemeier, T., Sulpice, T., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m016410 · Cited by 78
HDL-cholesterol and cardiovascular disease: rethinking our approach
Siddiqi, H. K., Kiss, D., & Rader, D. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000211 · Cited by 77
When should we measure lipoprotein (a)?
Kostner, K., März, W., & Kostner, G. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht053 · Cited by 77
Relationship Between Lipid Profiles and Hypertension: A Cross-Sectional Study of 62,957 Chinese Adult Males
Chen, S., & Cheng, W. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.895499 · Cited by 77
High-Density Lipoproteins in the Prevention of Cardiovascular Disease: Changing the Paradigm
Tuteja, S., & Rader, D. J. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.79 · Cited by 77
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
Kühnast, S., van der Tuin, S. J. L., van der Hoorn, J. W. A., van Klinken, J. B., Simic, B., Pieterman, E. J., Havekes, L. M., Landmesser, U., Lüscher, T. F., van Dijk, K. W., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu319 · Cited by 79
Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease
Visconti, L., Benvenga, S., Lacquaniti, A., Cernaro, V., Bruzzese, A., Conti, G., Buemi, M., & Santoro, D. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.08.002 · Cited by 75
Association of Lipoprotein(a) With Recurrent Ischemic Events Following Percutaneous Coronary Intervention
Yoon, Y., Ahn, J., Kang, D., Lee, P. H., Kang, S., Park, D., Lee, S., Kim, Y., Han, K. H., Lee, C. W., et al. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.07.042 · Cited by 72
Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study
Robins, S. J., Lyass, A., Brocia, R. W., Massaro, J. M., & Vasan, R. S. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.01.046 · Cited by 72
The renaissance of lipoprotein(a): Brave new world for preventive cardiology?
Ellis, K. L., Boffa, M. B., Sahebkar, A., Koschinsky, M. L., & Watts, G. F. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.09.001 · Cited by 71
Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels
Nelson, A. J., Sniderman, A. D., Ditmarsch, M., Dicklin, M. R., Nicholls, S. J., Davidson, M. H., & Kastelein, J. J. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169417 · Cited by 72
Self-citation
Effects of High-Density Lipoprotein Elevation With Cholesteryl Ester Transfer Protein Inhibition on Insulin Secretion
Siebel, A. L., Natoli, A. K., Yap, F. Y. T., Carey, A. L., Reddy-Luthmoodoo, M., Sviridov, D., Weber, C. I. K., Meneses‐Lorente, G., Maugeais, C., Forbes, J. M., et al. (2013) · Circulation Research · doi:10.1161/circresaha.113.300689 · Cited by 71
Regression of Atherosclerosis: Insights from Animal and Clinical Studies
Feig, J. E. (2014) · Annals of Global Health · doi:10.1016/j.aogh.2013.12.001 · Cited by 71
Biphenyl-Substituted Oxazolidinones as Cholesteryl Ester Transfer Protein Inhibitors: Modifications of the Oxazolidinone Ring Leading to the Discovery of Anacetrapib
Smith, C. J., Ali, A., Hammond, M. L., Li, H., Lu, Z., Napolitano, J. B., Taylor, G. E., Thompson, C. F., Anderson, M. S., Chen, Y., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200484c · Cited by 70
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
Landray, M., & REVEAL Collaborative Group (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.02.021 · Cited by 72
Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective
Mohammadpour, A. H., & Akhlaghi, F. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0071-8 · Cited by 70
Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: systematic review and meta-analysis of trials
Khan, S. U., Khan, M. U., Valavoor, S., Khan, M. S., Okunrintemi, V., Mamas, M. A., Leucker, T. M., Blaha, M. J., & Michos, E. D. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319871733 · Cited by 67
Nonstatin Therapies for Management of Dyslipidemia: A Review
Sando, K. R., & Knight, M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.001 · Cited by 69
Atherosclerosis: lessons from LXR and the intestine
Bonamassa, B., & Moschetta, A. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.10.004 · Cited by 67
Should low high-density lipoprotein cholesterol (HDL-C) be treated?
Toth, P. P., Barylski, M., Nikolić, D., Rizzo, M., Montalto, G., & Banach, M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.11.002 · Cited by 67
Mendelian randomisation applied to drug development in cardiovascular disease: a review
Mokry, L. E., Ahmad, O. S., Forgetta, V., Thanassoulis, G., & Richards, J. B. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102438 · Cited by 67
The Therapeutic Role of Niacin in Dyslipidemia Management
Boden, W. E., Sidhu, M. S., & Toth, P. P. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413514481 · Cited by 69
Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation
Tardif, J., Rhainds, D., Brodeur, M. R., Zada, Y. F., Fouodjio, R., Provost, S., Boulé, M., Alem, S., Grégoire, J. C., L’Allier, P. L., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.116.001405 · Cited by 69
Future of Cholesteryl Ester Transfer Protein Inhibitors
Rader, D. J., & deGoma, E. M. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-163305 · Cited by 66
Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia
Burnett, J., Bell, D. A., Hooper, & Watts, G. F. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s28581 · Cited by 69
New lipid-lowering drugs: an update
Wierzbicki, A. S., Hardman, T. C., & Viljoen, A. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02867.x · Cited by 65
Impact of Lipoprotein(a) as Residual Risk on Long-Term Outcomes in Patients After Percutaneous Coronary Intervention
Konishi, H., Miyauchi, K., Kasai, T., Tsuboi, S., Ogita, M., Naito, R., Sai, E., Fukushima, Y., Katoh, Y., Okai, I., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.10.015 · Cited by 65
Cholesterol Efflux
Tall, A. R., Yvan‐Charvet, L., Westerterp, M., & Murphy, A. J. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300134 · Cited by 67
Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction
Gutstein, D. E., Krishna, R., Johns, D. G., Surks, H. K., Dansky, H. M., Shah, S., Mitchel, Y., Arena, J. P., & Wagner, J. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.271 · Cited by 64
Self-citation
How to control residual cardiovascular risk despite statin treatment: Focusing on HDL–cholesterol
Lim, S. K., Park, Y. M., Sakuma, I., & Koh, K. K. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.127 · Cited by 64
Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From ATVB Council
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
Emerging therapeutic agents to lower lipoprotein (a) levels
Kolski, B. C., & Tsimikas, S. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283598d81 · Cited by 64
Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients
Croyal, M., Ouguerram, K., Passard, M., Ferchaud‐Roucher, V., Chétiveaux, M., Billon‐Crossouard, S., de Gouville, A., Lambert, G. C., Krempf, M., & Nobécourt, E. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305835 · Cited by 62
Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis
Riaz, H., Khan, S. U., Rahman, H., Shah, N. P., Kaluski, E., Lincoff, A. M., & Nissen, S. E. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487318816495 · Cited by 61
On- and Off-Target Pharmacology of Torcetrapib
Johns, D. G., Duffy, J., Fisher, T. S., Hubbard, B. K., & Forrest, M. J. (2012) · Drugs · doi:10.2165/11599310-000000000-00000 · Cited by 60
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk
Arsenault, B. J., Petrides, F., Tabet, F., Bao, W., Hovingh, G. K., Boekholdt, S. M., Ramin‐Mangata, S., Meilhac, O., DeMicco, D. A., Rye, K., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.001 · Cited by 60
Self-citation
Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk
Masson, W. M., Lobo, M., Siniawski, D. A., Huerin, M. S., Molinero, G., Valéro, R., & Nogueira, J. P. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.02.005 · Cited by 60
Tolerability, pharmacokinetics and pharmacodynamics of TA ‐8995, a selective cholesteryl ester transfer protein ( CETP ) inhibitor, in healthy subjects
Ford, J., Lawson, M., Fowler, D., Maruyama, N., Mito, S., Tomiyasu, K., Kinoshita, S., Suzuki, C., Kawaguchi, A., Round, P., et al. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12380 · Cited by 59
Treating Coronary Disease and the Impact of Endothelial Dysfunction
Matsuzawa, Y., Guddeti, R. R., Kwon, T., Lerman, L. O., & Lerman, A. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2014.10.004 · Cited by 61
A Comparison of the Theoretical Relationship between HDL Size and the Ratio of HDL Cholesterol to Apolipoprotein A-I with Experimental Results from the Women's Health Study
Mazer, N. A., Giulianini, F., Paynter, N. P., Jordan, P., & Mora, S. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.196949 · Cited by 59
Insight into rheumatological cause and effect through the use of Mendelian randomization
Robinson, P. C., Choi, H. K., Do, R., & Merriman, T. R. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.102 · Cited by 59
Relationship between lipoprotein concentrations and short-term and 1-year mortality in intensive care unit septic patients: results from the HIGHSEPS study
Tanaka, S., Stern, J., Bouzid, D., Robert, T., Dehoux, M., Snauwaert, A., Zappella, N., Cournot, M., Lortat‐Jacob, B., Augustin, P., et al. (2021) · Annals of Intensive Care · doi:10.1186/s13613-021-00800-0 · Cited by 58
Mechanistic systems modeling to guide drug discovery and development
Schmidt, B. J., Papin, J. A., & Musante, C. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.09.003 · Cited by 59
Role of HDL in Those with Diabetes
Santos‐Gallego, C. G., & Rosenson, R. S. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0512-5 · Cited by 59
Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging study
Ballantyne, C. M., Miller, M. J., Niesor, E. J., Burgess, T., Kallend, D. G., & Stein, E. A. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.11.017 · Cited by 59
Lipid Exchange Mechanism of the Cholesteryl Ester Transfer Protein Clarified by Atomistic and Coarse-grained Simulations
Koivuniemi, A., Vuorela, T., Kovanen, P. T., Vattulainen, I., & Hyvönen, M. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002299 · Cited by 59
Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases
Shinkai, H. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s25238 · Cited by 57
Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Murphy, A. J., Funt, S. A., Gorman, D. J., Tall, A. R., & Wang, N. (2013) · Circulation Research · doi:10.1161/circresaha.113.301112 · Cited by 57
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib
Davidson, M., Liu, S. X., Barter, P., Brinton, E. A., Cannon, C. P., Gotto, A. M., Leary, E. T., Shah, S., Stepanavage, M., Mitchel, Y., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m032615 · Cited by 56
Self-citation
Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis
Pantelidis, P., Oikonomou, E. K., Lampsas, S., Zakynthinos, G. Ε., Lysandrou, A., Kalogeras, K. I., Katsianos, E., Theofilis, P., Siasos, G., Vavuranakis, M., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad062 · Cited by 56
Overcoming Challenges With Statin Therapy
Spence, J. D., & Dresser, G. K. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002497 · Cited by 57
Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination
Krishna, R., Gheyas, F., Liu, Y., Hagen, D., Walker, B., Chawla, A., Côté, J., Blaustein, R. O., & Gutstein, D. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.700 · Cited by 56
Detrimental Effect of Hypercholesterolemia on High-Density Lipoprotein Particle Remodeling in Pigs
Padró, T., Cubedo, J., Camino-López, S., Béjar, M. T., Ben‐Aicha, S., Mendieta, G., Escolá‐Gil, J. C., Escate, R., Gutiérrez, M., Casaní, L., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.05.018 · Cited by 57
Dysfunctional High-Density Lipoprotein Cholesterol and Coronary Artery Disease: A Narrative Review
Madaudo, C., Bono, G., Ortello, A., Astuti, G., Mingoia, G., Galassi, A. R., & Sucato, V. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14090996 · Cited by 57
Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials
Kühnast, S., Fiocco, M. F., van der Hoorn, J. W. A., Princen, H. M. G., & Jukema, J. W. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.089 · Cited by 58
An Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias
Rached, F. H., Chapman, M. J., & Kontush, A. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.85 · Cited by 55
Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Taheri, H., Filion, K. B., Windle, S. B., Reynier, P., & Eisenberg, M. J. (2020) · Cardiology · doi:10.1159/000505365 · Cited by 54
Impact of lipoprotein(a) on long-term outcomes in patients with diabetes mellitus who underwent percutaneous coronary intervention
Konishi, H., Miyauchi, K., Shitara, J., Endo, H., Wada, H., Doi, S., Naito, R., Tsuboi, S., Ogita, M., Dohi, T., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.08.067 · Cited by 53
Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients
Nicholls, S. J., Ruotolo, G., Brewer, H. B., Wang, M.-D., Liu, L., Willey, M. B., Deeg, M. A., Krueger, K. A., & Nissen, S. E. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.11.014 · Cited by 53
New Frontiers in Lp(a)-Targeted Therapies
Borrelli, M. J., Youssef, A., Boffa, M. B., & Koschinsky, M. L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.01.004 · Cited by 55
Dissecting the Mechanisms Underlying Unusually Successful Human Health Span and Life SpanPreprint
Milman, S., & Barzilai, N. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025098 · Cited by 53
Human genetics of HDL: Insight into particle metabolism and function
Brunham, L. R., & Hayden, M. R. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.01.001 · Cited by 54
Treatment of lipid disorders in obesity
Tonstad, S., & Després, J. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.83 · Cited by 52
Antisense Oligonucleotides Targeting Lipoprotein(a)
Langsted, A., & Nordestgaard, B. G. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0792-8 · Cited by 50
Efecto del aceite de sacha inchi (Plukenetia volúbilis L) sobre el perfil lipídico en pacientes con hiperlipoproteinemia
Garmendia, F., Pando, R., & Ronceros, G. (2014) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2011.284.426 · Cited by 49
Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects
Kawashiri, M., Hayashi, K., Konno, T., Fujino, N., Ino, H., & Yamagishi, M. (2013) · Heart and Vessels · doi:10.1007/s00380-013-0391-5 · Cited by 48
HDL re-examined
Hovingh, G. K., Rader, D. J., & Hegele, R. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000161 · Cited by 51
Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications
Bonilha, I., Zimetti, F., Zanotti, I., Papotti, B., & Sposito, A. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112233 · Cited by 48
Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention
Suwa, S., Ogita, M., Miyauchi, K., Sonoda, T., Konishi, H., Tsuboi, S., Wada, H., Naito, R., Dohi, T., Kasai, T., et al. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.38794 · Cited by 46
Theory and practical use of Bayesian methods in interpreting clinical trial data: a narrative review
Ferreira, D., Barthoulot, M., Pottecher, J., Torp, K. D., Diemunsch, P. A., & Meyer, N. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.04.092 · Cited by 46
Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?
Mani, P., & Rohatgi, A. K. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0521-x · Cited by 47
Rationale for cholesteryl ester transfer protein inhibition
Hewing, B., & Fisher, E. A. A. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328353ef1d · Cited by 45
Causal Relevance of Blood Lipid Fractions in the Development of Carotid Atherosclerosis
Shah, S. H., Casas, J. P., Drenos, F., Whittaker, J. C., Deanfield, J. E., Swerdlow, D. I., Holmes, M. V., Mika Kivimaki, B., Langenberg, C., Wareham, N. J., et al. (2012) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.112.963140 · Cited by 45
Self-citation
Familial Hypercholesterolemia: Present and Future Management
Sjouke, B., Kusters, D. M., Kastelein, J. J. P., & Hovingh, G. K. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0219-9 · Cited by 45
The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis
Dangas, K., Navar, A.-M., & Kastelein, J. J. P. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac025 · Cited by 44
Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?
Gotto, A. M. (2011) · PubMed Central · Cited by 44
Self-citation
Phenotypes and Genotypes of High Density Lipoprotein Cholesterol in Exceptional Longevity
Milman, S., Atzmon, G., Crandall, J. P., & Barzilai, N. (2013) · Current Vascular Pharmacology · doi:10.2174/1570161111666131219101551 · Cited by 46
Pharmacotherapies for lipid modification: beyond the statins
Gotto, A. M., & Moon, J. E. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.117 · Cited by 45
Self-citation
Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study
Gotto, A. M., Kher, U. A., Chatterjee, M. S., Liu, Y., Li, X. S., Vaidya, S., Cannon, C. P., Brinton, E. A., Moon, J. E., Shah, S., et al. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414529621 · Cited by 44
Self-citation
Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study
Verbeek, R., Boekholdt, S. M., Stoekenbroek, R. M., Hovingh, G. K., Witztum, J. L., Wareham, N. J., Sandhu, M. S., Khaw, K., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p066258 · Cited by 44
Molecular Nutrition Fats
Enkhmaa, B., & Berglund, L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811297-7.00013-5 · Cited by 44
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial
Nicholls, S. J., Ray, K. K., Ballantyne, C. M., Beacham, L. A., Miller, D. L., Ruotolo, G., Nissen, S. E., & Riesmeyer, J. S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.008 · Cited by 44
Genetic variation in cholesterol ester transfer protein, serum CETP activity, and coronary artery disease risk in Asian Indian diabetic cohort
Schierer, A., Been, L. F., Ralhan, S. K., Wander, G. S., Aston, C. E., & Sanghera, D. K. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834dc9ef · Cited by 43
Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein
Duwensee, K., Schwaiger, S., Tancevski, I., Eller, K., Eck, M. V., Markt, P., Linder, T., Stanzl, U., Ritsch, A., Patsch, J. R., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.07.023 · Cited by 43
Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy
Gaudet, D., Drouin‐Chartier, J., & Couture, P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.12.019 · Cited by 43
Association between high-density lipoprotein cholesterol and all-cause mortality in the general population of northern China
Li, X., Guan, B., Wang, Y., Tse, G., Zou, F., Waleed, K. B., Xia, Y., Wu, S., & Sun, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50924-4 · Cited by 43
Association between the Interleukin-6 Promoter Polymorphism −174G/C and Serum Lipoprotein(a) Concentrations in Humans
Berthold, H. K., Laudes, M., Krone, W., & Gouni‐Berthold, I. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024719 · Cited by 43
Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease
Hopewell, J. C., Seedorf, U., Farrall, M., Parish, S., Kyriakou, T., Goel, A., Hamsten, A., Collins, R., Watkins, H. C., & Clarke, R. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12187 · Cited by 43
Developing Medicines That Mimic the Natural Successes of the Human Genome
Kathiresan, S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.049 · Cited by 43

Authors: Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., Zafarino, J., Mitchel, Y., & Barter, P.
Affiliations: Brigham and Women's Hospital (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Radiant Research (United States) (US)
University of Utah (US)
The Heart Research Institute (AU)
ORCID: Cannon, Christopher P.
Dansky, Hayes M.
Davidson, Michael
Brinton, Eliot A.
Gotto, Antonio M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2010-12-16
Volume: 363
Issue: 25
Pages: 2406-2415
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1009744
OpenAlex: W2090464684
Cited by: 749
References: 17
Citations by year: 2026: 13 · 2025: 7 · 2024: 13 · 2023: 13 · 2022: 16 · 2021: 18 · 2020: 18 · 2019: 21 · 2018: 26 · 2017: 54 · 2016: 68 · 2015: 83 · 2014: 83 · 2013: 92 · 2012: 116
FWCI: 107.18
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords: anacetrapib, cholesteryl ester transfer protein inhibitors, coronary artery disease, LDL cholesterol lowering, HDL cholesterol, statin combination therapy, cardiovascular safety, cardiovascular events, drug safety, high-risk patients, lipid-lowering therapy, blood pressure, electrolytes, aldosterone, Bayesian hierarchical model, cardiovascular hospitalization
MeSH terms: Adult, Aged, Anticholesteremic Agents, Bayes Theorem, Combined Modality Therapy, Coronary Disease, Double-Blind Method, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Oxazolidinones, Cholesterol Ester Transfer Proteins, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks